おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
Desentum
About
Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- €1.90M
- Industries
- Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2011
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 30, 2018 | Grant | €1.90M | 1 | — | — | Detail |
| Jan 23, 2017 | Series A | €1.85M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
European Innovation Council
|
— | Grant |
|
|
— | Series A |
